Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

The role of microbial proteases in colitis

FY 2015-16

Summary
Approximately 1 in every 150 Canadians live with inflammatory bowel disease (IBD), a group of gastrointestinal disorders with unknown cause. The two main forms of IBD, ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic inflammation of the gastrointestinal tract. Changes in gut bacterial communities (dysbiosis) can contribute to inflammation, and indeed, microbiota-modulating therapies for IBD have shown some efficacy. Yet, little is known regarding how specific bacterial species influence susceptibility to inflammation. While pro-inflammatory molecules such as “proteases” produced by inflamed tissues in patients with IBD can amplify inflammation, the role of proteases produced by bacterial dysbiotic communities in IBD, has been overlooked. The aim of this study is to investigate whether the intestinal bacterial community, which is alterd in IBD, is a key regulator of proteolytic/anti-proteolytic balance in colitis. Mice that are initially free of bacteria (germ-free) will be colonized by gut bacteria from UC patients that have high proteolytic activity versus low proteolytic activity, then treated with a colitis-inducing agent to determine if bacterial proteases can contribute to disease severity. Thus far, my preliminary data indicates that mice colonized with high proteolytic bacteria develop higher severity of experimental colitis and the activity is transferrable to the mouse intestine. Results from this study will offer insight into the specific mechanism of host-microbiota interactions and will allow development of more effective microbiota-modulating therapies for IBD patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
349930
Name
Dong Jasmine
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of microbial proteases in colitis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Inflammatory Bowel Disease; Intestinal Barrier Function; Microbiota; Proteases
Abstract
Approximately 1 in every 150 Canadians live with inflammatory bowel disease (IBD), a group of gastrointestinal disorders with unknown cause. The two main forms of IBD, ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic inflammation of the gastrointestinal tract. Changes in gut bacterial communities (dysbiosis) can contribute to inflammation, and indeed, microbiota-modulating therapies for IBD have shown some efficacy. Yet, little is known regarding how specific bacterial species influence susceptibility to inflammation. While pro-inflammatory molecules such as “proteases” produced by inflamed tissues in patients with IBD can amplify inflammation, the role of proteases produced by bacterial dysbiotic communities in IBD, has been overlooked. The aim of this study is to investigate whether the intestinal bacterial community, which is alterd in IBD, is a key regulator of proteolytic/anti-proteolytic balance in colitis. Mice that are initially free of bacteria (germ-free) will be colonized by gut bacteria from UC patients that have high proteolytic activity versus low proteolytic activity, then treated with a colitis-inducing agent to determine if bacterial proteases can contribute to disease severity. Thus far, my preliminary data indicates that mice colonized with high proteolytic bacteria develop higher severity of experimental colitis and the activity is transferrable to the mouse intestine. Results from this study will offer insight into the specific mechanism of host-microbiota interactions and will allow development of more effective microbiota-modulating therapies for IBD patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dong, Jasmine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~